0.9469 USD
-0.03 (-3.38%)
Last: Jan 30, 2026, 11:49 AM
Overall CRDL gets a fundamental rating of 1 out of 10. We evaluated CRDL against 190 industry peers in the Pharmaceuticals industry. CRDL has a bad profitability rating. Also its financial health evaluation is rather negative. CRDL does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- CRDL had negative earnings in the past year.
- CRDL had a negative operating cash flow in the past year.
- In the past 5 years CRDL always reported negative net income.
- In the past 5 years CRDL always reported negative operating cash flow.
1.2 Ratios
- The Return On Assets of CRDL (-268.65%) is worse than 91.58% of its industry peers.
- CRDL has a Return On Equity of -363.82%. This is in the lower half of the industry: CRDL underperforms 76.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -268.65% | ||
| ROE | -363.82% | ||
| ROIC | N/A |
ROA(3y)-80.54%
ROA(5y)-81.5%
ROE(3y)-102.38%
ROE(5y)-100.84%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for CRDL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- Compared to 1 year ago, CRDL has more shares outstanding
- The number of shares outstanding for CRDL has been increased compared to 5 years ago.
- The debt/assets ratio for CRDL is higher compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of -7.26, we must say that CRDL is in the distress zone and has some risk of bankruptcy.
- The Altman-Z score of CRDL (-7.26) is worse than 67.37% of its industry peers.
- A Debt/Equity ratio of 0.01 indicates that CRDL is not too dependend on debt financing.
- CRDL has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: CRDL outperforms 57.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.26 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- CRDL has a Current Ratio of 3.89. This indicates that CRDL is financially healthy and has no problem in meeting its short term obligations.
- CRDL has a Current ratio of 3.89. This is comparable to the rest of the industry: CRDL outperforms 58.95% of its industry peers.
- CRDL has a Quick Ratio of 3.89. This indicates that CRDL is financially healthy and has no problem in meeting its short term obligations.
- With a decent Quick ratio value of 3.89, CRDL is doing good in the industry, outperforming 60.53% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.89 | ||
| Quick Ratio | 3.89 |
3. Growth
3.1 Past
- CRDL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 24.07%, which is quite impressive.
EPS 1Y (TTM)24.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to grow by 24.61% on average over the next years. This is a very strong growth
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y22%
EPS Next 2Y-5.51%
EPS Next 3Y19.19%
EPS Next 5Y24.61%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- CRDL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year CRDL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as CRDL's earnings are expected to grow with 19.19% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.51%
EPS Next 3Y19.19%
5. Dividend
5.1 Amount
- No dividends for CRDL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CARDIOL THERAPEUTICS INC-A / CRDL FAQ
What is the ChartMill fundamental rating of CARDIOL THERAPEUTICS INC-A (CRDL) stock?
ChartMill assigns a fundamental rating of 1 / 10 to CRDL.
What is the valuation status of CARDIOL THERAPEUTICS INC-A (CRDL) stock?
ChartMill assigns a valuation rating of 0 / 10 to CARDIOL THERAPEUTICS INC-A (CRDL). This can be considered as Overvalued.
Can you provide the profitability details for CARDIOL THERAPEUTICS INC-A?
CARDIOL THERAPEUTICS INC-A (CRDL) has a profitability rating of 0 / 10.
What is the expected EPS growth for CARDIOL THERAPEUTICS INC-A (CRDL) stock?
The Earnings per Share (EPS) of CARDIOL THERAPEUTICS INC-A (CRDL) is expected to grow by 22% in the next year.